Mbx biosciences announces closing of upsized initial public offering, including full exercise of underwriters' option to purchase additional shares

Carmel, ind., sept. 16, 2024 (globe newswire) -- mbx biosciences, inc. (nasdaq: mbx) (“mbx biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. the aggregate gross proceeds to mbx biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses.
MBX Ratings Summary
MBX Quant Ranking